natgillin/translations-raw huggingface dataset:
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alaninske transferaze (ALT), aspartatne transferaze (AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz,, alaninske transferaze (ALT), aspartatne transferaze (AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly,especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alanin transferaze (ALT), aspartat transferaze (AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alaninske transferaze (ALT), aspartatne transferaze (AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna asimptomatska zvišanja vrednosti jetrnih aminotransferaz, (alaninske aminotransferaze – ALT, aspartatne aminotransferaze – AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepaticaminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz,, alaninske transferaze (ALT), aspartatne transferaze (AST), posebno na začetku zdravljenja.
Transition from other insulins to ABASAGLAR
Prehod z drugih insulinov na zdravilo ABASAGLAR
Transition from other insulins to Toujeo
Prehod z drugih insulinov na zdravilo Toujeo
Transitory scratching, erythema or hair loss at the application site may occur.
Lahko se pojavi prehodno praskanje, rdečina ali izpadanje dlake na mestu nanosa.
transitory vomiting
bruhanje,
Translarna 1,000 mg granules for oral suspension
Translarna 1000 mg zrnca za peroralno suspenzijo
Translarna 1,000 mg granules for oral suspension ataluren
Translarna 1000 mg zrnca za peroralno suspenzijo ataluren
Translarna 125 mg granules for oral suspension
Translarna 125 mg zrnca za peroralno suspenzijo
Translarna 125 mg granules for oral suspension Translarna 250 mg granules for oral suspension Translarna 1000 mg granules for oral suspension Ataluren
Translarna 125 mg zrnca za peroralno suspenzijo Translarna 250 mg zrnca za peroralno suspenzijo Translarna 1000 mg zrnca za peroralno suspenzijo ataluren
Translarna 250 mg granules for oral suspension
Translarna 250 mg zrnca za peroralno suspenzijo
Translarna can only be obtained with a prescription and treatment should be started by a specialist doctor experienced in the management of Duchenne/Becker muscular dystrophy.
Izdaja zdravila Translarna je le na recept, zdravljenje z njim pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem Duchennove/Beckerjeve mišične distrofije.
Translarna has been given ‘conditional approval’.
Zdravilo Translarna je pridobilo „pogojno dovoljenje za promet“.
Translarna has been studied in one main study involving 174 patients with Duchenne muscular dystrophy who were able to walk, where two doses of Translarna (40 mg/kg daily and 80 mg/kg daily) were compared with placebo (a dummy treatment).
Zdravilo Translarna so proučevali v eni glavni študiji s 174 bolniki z Duchennovo mišično distrofijo, ki so lahko hodili, v kateri so dva odmerka zdravila Translarna (40 mg/kg na dan in 80 mg/kg na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine).
Translarna is a medicine that contains the active substance ataluren.
Translarna je zdravilo, ki vsebuje zdravilno učinkovino ataluren.
Translarna is available as granules (100, 250 and 1,000 mg) to be taken by mouth after mixing them with liquid or semi-solid food (such as yogurt).
Zdravilo Translarna je na voljo v obliki zrnc (100 mg, 250 mg in 1 000 mg), ki se jemljejo skozi usta, potem ko se zmešajo s tekočino ali mehko hrano (na primer z jogurtom).
Translarna is available in 3 strengths, each containing 125 mg, 250 mg and 1,000 mg of the active substance, called ataluren.
Zdravilo Translarna je na voljo v 3 jakostih, ki vsebujejo 125 mg, 250 mg ali 1000 mg zdravilne učinkovine, imenovane ataluren.
Translarna is available in the following sachet strengths: 125 mg, 250 mg and 1000 mg of ataluren per sachet.
Zdravilo Translarna je na voljo v vrečicah z naslednjimi jakostmi: 125 mg, 250 mg in 1 000 mg atalurena na vrečico.
Translarna is for use in patients whose disease is due to the presence of certain defects (called nonsense mutations) in the dystrophin gene which prematurely stop the production of a normal dystrophin protein, leading to a shortened dystrophin protein that does not function properly.
Zdravilo Translarna je namenjeno za uporabo pri bolnikih, pri katerih je bolezen posledica prisotnosti določenih okvar (imenovanih nesmiselne mutacije) gena za distrofin, ki predčasno zaustavijo tvorbo normalne beljakovine distrofina, zaradi česar nastane krajša beljakovina distrofin, ki ne deluje pravilno.
Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older (see section 5.1).
Zdravilo Translarna je indicirano za zdravljenje Duchennove mišične distrofije, ki je posledica nesmiselne mutacije gena za distrofin, pri mobilnih bolnikih, starih 5 let ali več (glejte poglavje 5.1).
Translarna is taken three times a day, and the recommended dose is 10 mg/kg (10 mg per kilogram body weight) in the morning, 10 mg/kg at
Zdravilo Translarna se jemlje trikrat na dan, pri čemer je priporočeni odmerek 10 mg/kg (10 mg na kilogram telesne mase) zjutraj, 10 mg/kg zgodaj popoldne in 20 mg/kg zvečer (skupni dnevni odmerek je torej 40 mg/kg).
Translarna is used in the small group of Duchenne patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Zdravilo Translarna se uporablja pri majhni skupini bolnikov z Duchennovo mišično distrofijo, ki je posledica posebne genetske okvare (imenovane „nesmiselna mutacija“) gena za distrofin.
Translarna is used to treat patients aged 5 years and older, who are able to walk.
Zdravilo Translarna se uporablja za zdravljenje bolnikov, starih 5 let ali več, ki lahko hodijo.
Translarna must not be used at the same time as certain antibiotics known as aminoglycosides when these are given by injection into a vein.
Zdravilo Translarna se ne sme uporabljati sočasno z določenimi antibiotiki, imenovanimi aminoglikozidi, ki se dajejo z injiciranjem v veno.
Transmissible agents
Povzročitelji nalezljivih bolezni
Transmission
Prenos cepilnega virusa
Transmission
Širjenje okužbe
Transmission of HIV: While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded.
Prenos HIV: Čeprav se je izkazalo, da učinkovita virusna supresija s protiretrovirusno terapijo bistveno zmanjša tveganje spolnega prenosa, preostalega tveganja ni mogoče izključiti.
Transparent (uncoloured) capsules containing a white powder, with “IDL 150” printed in black above a black bar and company logo ) printed in black below the black bar.
Prosojne (neobarvane) kapsule, ki vsebujejo bel prašek in imajo črno tiskano oznako "IDL 150" nad črno črto in črno tiskan zaščitni znak družbe ) pod črno črto.
Transparent (uncoloured) capsules containing a white powder, with “IDL 300” printed in blue above a blue bar and company logo ) printed in blue below the blue bar.
Prosojne (neobarvane) kapsule, ki vsebujejo bel prašek in imajo modro tiskano oznako "IDL 300" nad modro črto in modro tiskan zaščitni znak družbe ) pod modro črto.
Transparent orange capsules containing a white powder, with the product code “GPL50” printed in black above and the company logo ) printed in black below a black bar.
Prozorne oranžne kapsule, ki vsebujejo bel prašek in imajo natisnjeno črno oznako zdravila "GPL50" nad črno črto in črn zaščitni znak družbe ) pod črno črto.
Transparent PVC/PVdC - Aluminium blisters.
Prozorni neprepustni PVC/PVdC - aluminijasti pretisni omoti.
Transparent PVC/PVdC – aluminium blisters in pack sizes of 100 or 300 or 100 x 1 capsules per carton.
Prozorni PVC/PVdC – aluminijasti pretisni omoti v pakiranjih po 100 ali 300 ali 100 x 1 kapsula v škatli.
Transparent PVC/PVdC – aluminium blisters.
Prozorni pretisni omot iz PVC/PVdC-aluminija.
Transparent PVC/PVdC-aluminium blisters in pack sizes of 50 or 150 or 50 x 1 tablets per carton.
Prozorni PVC/PVdC – aluminijasti pretisni omoti v pakiranjih po 50 ali 150 ali 50 x 1 tableta v škatli.
TRANSPARENT SEALED PLASTIC CASING LABEL (2 vial pack)
PROZOREN, ZATESNJEN PLASTIČEN OVOJ (pakiranje z 2 vialama)
TRANSPARENT SEALED PLASTIC CASING LABEL (3 vial pack)
PROZOREN, ZATESNJEN PLASTIČEN OVOJ (pakiranje s 3 vialami)
Transparent Tip
Prozorna konica
Transparent window
prozorno okence
transplant failure, transfusion reaction, wound dehiscence, fracture, tendon rupture, procedural hypotension, procedural hypertension, post-procedural haematoma, procedural pain, procedural headache, contusion
odpoved presadka, transfuzijska reakcija, dehiscenca rane, zlom, ruptura tetive, hipotenzija med posegom, hipertenzija med posegom, hematom po posegu, bolečina med posegom, glavobol med posegom, kontuzija
Transplant patients receiving immunosuppressive regimens (e.g. systemic tacrolimus) are at increased risk for developing lymphoma; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.
Bolnike s presajenimi organi, ki dobivajo imunosupresive (npr. sistemski takrolimus), bolj ogroža pojav limfoma; zato je treba bolnike, ki dobivajo zdravilo Protopic in se jim pojavi limfadenopatija, spremljati, da bi se prepričali o njenem izginotju.
Transplant patients receiving immunosuppressive regimens involving combinations with or without basiliximab are at increased risk of developing lymphoproliferative disorders (LPDs) (such as lymphoma) and opportunistic infections (such as cytomegalovirus, CMV).
Pri bolnikih s presajenimi organi, ki prejemajo imunosupresivno shemo zdravljenja s kombinacijo z baziliksimabom ali brez njega, je povečana nevarnost nastanka limfoproliferativnih bolezni (LPD), kot je na primer limfom, in oportunističnih okužb, kot je na primer okužba s citomegalovirusom (CMV).
Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication.
Prejemniki presajenih organov in bolniki z dekompenzirano cirozo so v večji nevarnosti glede aktivne replikacije virusa.
Transplantation recipients are at greater risk from active viral replication.
Prejemniki presajenih organov so v večji nevarnosti glede aktivne replikacije virusa.
Transport filled syringe to point of administration.
Prenesite napolnjeno brizgo na mesto, kjer bo zdravilo uporabljeno.
Transport medium (Dulbecco’s Modified Eagles Medium supplemented with L-glutamine) Fibrin support.
transportno gojišče ((D-MEM (Dulbecco’s Modified Eagles Medium) obogateno z L-glutaminom fibrinska podpora
Transport medium (Dulbecco’s Modified Eagles Medium supplemented with L-glutamine) Fibrin support.
Transportno gojišče (D-MEM (Dulbecco’s Modified Eagles Medium) obogaten z L-glutaminom) fibrinska podpora
Transverse myelitis, central nervous system demyelinating disorders
transverzni mielitis, demielinizirajoče bolezni osrednjega
Transverse myelitis, central nervous system demyelinating disorders (multiple sclerosis-like disease and optic neuritis), peripheral demyelinating disorders (such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy).
vrtoglavica, omotica, hipestezija, parestezije epileptični napadi, nevropatija transverzni mielitis, demielinizirajoče bolezni osrednjega živčevja (bolezen, podobna multipli sklerozi, in optični nevritis), periferne demielinizirajoče bolezni (na primer Guillain-Barréjev sindrom, kronična vnetna demielinizirajoča polinevropatija in multifokalna motorična nevropatija)
TRANxITION (study 1100.1526) is a Phase 3 study to evaluate safety and antiviral activity in patients switching from Viramune immediate-release to Viramune prolonged-release.
TRANxITION (1100.1526) je študija 3. faze, v kateri ocenjujejo varnost in protivirusno delovanje pri bolnikih, ki zamenjajo zdravilom Viramune s takojšnjim sproščanjem za zdravilo Viramune s podaljšanim sproščanjem.
Trastuzum ab
trastuzu
trastuzumab
trastuzumaba
trastuzumab
trastuzumabom
trastuzumab
uporabljati
Trastuzumab binds with high affinity and specificity to sub-domain IV, a juxta-membrane region of HER2’s extracellular domain.
Trastuzumab se z visoko afiniteto in specifičnostjo veže na poddomeno IV, jukstamembransko regijo zunajcelične domene HER2.
Trastuzumab emtansine arm: trastuzumab emtansine 3.6 mg/kg intravenously over 30-90 minutes on Day 1 of a 21-day cycle
kupina s trastuzumabom emtanzinom: trastuzumab emtanzin 3,6 mg/kg intravensko v 30 do 90 minutah 1. dan 21-dnevnega ciklusa;
Trastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in patients with mild or moderate hepatic dysfunction was within the range observed in patients with normal hepatic function.
Izpostavljenost trastuzumabu emtanzinu (AUC) v 3. ciklusu po dajanju ponavljajočih se odmerkov bolnikom z blago ali zmerno okvarjenim delovanjem jeter je bila v območju, ki so ga opazili pri bolnikih z normalnim delovanjem jeter.
Trastuzumab emtansine has no or negligible influence on the ability to drive and use machines.
Trastuzumab emtanzin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Trastuzumab emtansine has not been studied in patients with serum transaminases > 2.5  ULN or total bilirubin > 1.5  ULN prior to initiation of treatment.
Trastuzumab emtanzin ni bil raziskan pri bolnikih, ki imajo pred uvedbo zdravljenja serumske transaminaze > 2,5  ZNM ali celokupni bilirubin > 1,5  ZNM.
Trastuzumab emtansine has not been studied in patients with severe hepatic impairment (Child-Pugh class C).
Trastuzumaba emtanzina niso preučevali pri bolnikih s hudo jetrno okvaro (razred C po Child-Pughovi lestvici).
Trastuzumab emtansine is expected to undergo deconjugation and catabolism by means of proteolysis in cellular lysosomes.
Pričakovano je, da se trastuzumab emtanzin dekonjugira in katabolizira s proteolizo v celičnih lizosomih.
Trastuzumab emtansine was not studied in patients with severe hepatic impairment.
Pri bolnikih s hudo jetrno okvaro trastuzumaba emtanzina niso preučevali.
Trastuzumab emtansine when administered intravenously every 3 weeks exhibited linear PK across doses ranging from 2.4 to 4.8 mg/kg; patients who received doses less than or equal to 1.2 mg/kg had faster clearance.
Na 3 tedne intravensko uporabljeni trastuzumab emtanzin je imel v razponu odmerkov od 2,4 do 4,8 mg/kg linearno farmakokinetiko; bolniki, ki so dobili odmerke, manjše ali enake 1,2 mg/kg, so imele hitrejši očistek.
Trastuzumab emtansine, like trastuzumab, binds to domain IV of the HER2 extracellular domain (ECD), as well as to Fcγ receptors and complement C1q.
Tako kot trastuzumab se tudi trastuzumab emtanzin veže na domeno IV zunajcelične domene (ECD – extracellular domain) HER2 ter na receptorje Fcγ in komplement C1q.
Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every three weeks.
Trastuzumab so dali intravensko v uvajalnem odmerku 8 mg/kg, nato pa v odmerku 6 mg/kg vsake tri tedne.
Trastuzumab washout
Izpiranje trastuzumaba
Traumatic haemorrhage
krvavitev pri poškodbi
Traumatic haemorrhage, post procedural haemorrhage, incision site haemorrhage
travmatske krvavitve, krvavitve po posegu, krvavitev na mestu vreza
TRAVATAN 40 micrograms/mL eye drops Travoprost
TRAVATAN 40 mikrogramov/ml kapljice za oko travoprost
TRAVATAN 40 micrograms/mL eye drops, solution
TRAVATAN 40 mikrogramov/ml kapljice za oko, raztopina
TRAVATAN 40 micrograms/mL eye drops, solution. travoprost
TRAVATAN 40 mikrogramov/ml kapljice za oko, raztopina travoprost
TRAVATAN is a liquid (a clear, colourless solution) supplied in a pack containing a 4 ml plastic bottle with a screw cap.
TRAVATAN je tekočina (bistra, brezbarvna raztopina), ki je na voljo v pakiranjih s 4 ml plastičnim kapalnim vsebnikom z navojno zaporko.
TRAVATAN may change the colour of your iris (the coloured part of your eye).
Zdravilo TRAVATAN lahko spremeni barvo šarenice (obarvani del očesa).
TRAVATAN may increase the length, thickness, colour and/or number of your eyelashes.
Zdravilo TRAVATAN lahko podaljša, odebeli ali obarva trepalnice in/ali poveča število trepalnic.
TRAVATAN may rarely cause breathlessness or wheezing or increase the symptoms of asthma.
Zdravilo TRAVATAN lahko v redkih primerih povzroči težko dihanje ali piskanje v pljučih ali poveča simptome astme.
TRAVATAN should not be used during pregnancy unless clearly necessary.
Zdravila TRAVATAN ne smete uporabljati pri nosečnicah, če to ni nujno.
travel or motion sickness, ringing in the ears (tinnitus) heart problems, such as slow, fast or irregular heart beat, or altered results during an electrocardiogram (ECG – QT prolongation)
potovalna bolezen ali kinetoza, zvenenje v ušesih (tinitus) težave s srcem, npr. počasen, hiter ali nepravilen srčni utrip, ali sprememba rezultatov elektrokardiograma (EKG – podaljšanje intervala QT)
Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/min).
Travoprost so raziskovali pri bolnikih z blago do hudo jetrno okvaro in pri tistih z blago do hudo ledvično okvaro (očistek kreatinina le 14 ml/min).
Travoprost has harmful pharmacological effects on pregnancy and/or the fetus/new-born child.
Travoprost ima škodljive farmakološke učinke na nosečnost in/ali plod oziroma novorojenega otroka.
Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/new-born child.
Travoprost ima škodljivo farmakološko delovanje na nosečnost in/ali na plod oz. nerojenega otroka.
Travoprost is a prostaglandin analogue (a man-made copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye.
Travoprost je analog prostaglandina (umetne kopije naravne snovi prostaglandina), ki deluje tako, da poveča odtok tekočine iz očesa.
Travoprost is a prostaglandin analogue which works by increasing the outflow of liquid of the eye, which lowers its pressure.
Travoprost je prostaglandinski analog, ki deluje tako, da poveča iztekanje prekatne vodke iz očesa in s tem zniža očesni tlak.
Travoprost may be absorbed through the skin.
Travoprost se lahko absorbira skozi kožo.
Travoprost must not be used in women of child bearing age/potential unless adequate contraceptive measures are in place (see section 5.3).
Travoprosta ne smejo uporabljati ženske v rodni dobi, ki bi lahko zanosile, če ne uporabljajo ustrezne kontracepcijske zaščite (glejte poglavje 5.3).
Travoprost on its own has been authorised in the European Union as Travatan since 2001.
Travoprost kot samostojna učinkovina je v Evropski uniji že odobren od leta 2001 pod imenom Travatan.
TRAY BACKING TEXT
BESEDILO NA HRBTU OMOTA
TRAY BACKING TEXT
BESEDILO NA PODSTAVKU ZA ZDRAVILO
TRAY FOR PRE-FILLED SYRINGE
PRETISNI OMOT ZA NAPOLNJENO INJEKCIJSKO BRIZGO
TRAY FOR PRE-FILLED SYRINGE WITH NEEDLE GUARD
PRETISNI OMOT ZA NAPOLNJENO INJEKCIJSKO BRIZGO S ŠČITNIKOM IGLE
TRAY TOP LID LABEL FOR 12 MG PACK
NALEPKA NA POKROVU PLADNJA ZA 12 MG PAKIRANJE
TRAY TOP LID LABEL FOR 4 MG PACK
NALEPKA NA POKROVU PLADNJA ZA 4 MG PAKIRANJE
TRAY UNDERSIDE OF LID STICKER FOR 12 MG PACK
NALEPKA NA NOTRANJI STRANI POKROVA PLADNJA 12 MG PAKIRANJE
TRAY UNDERSIDE OF LID STICKER FOR 4 MG PACK
NALEPKA NA NOTRANJI STRANI POKROVA PLADNJA ZA 4 MG PAKIRANJE
TRAZEC 120 mg film-coated tablets
TRAZEC 120 mg filmsko obložene tablete
Trazec 120 mg film-coated tablets are yellow, ovaloid tablets with “NVR” marked on one side and “TSL” on the other.
Trazec 120 mg filmsko obložene tablete so rumene, ovalne tablete z oznako “NVR” na eni ter “TSL” na drugi strani.
Trazec 120 mg film-coated tablets Nateglinide
Trazec 120 mg filmsko obložene tablete nateglinid
Trazec 120 mg tablets Nateglinide
Trazec 120 mg tablete nateglinid
TRAZEC 180 mg film-coated tablets
TRAZEC 180 mg filmsko obložene tablete
Trazec 180 mg film-coated tablets are red, ovaloid tablets with “NVR” marked on one side and “TSX” on the other.
Trazec 180 mg filmsko obložene tablete so rdeče, ovalne tablete z oznako “NVR” na eni ter “TSX” na drugi strani.
Trazec 180 mg film-coated tablets Nateglinide
Trazec 180 mg filmsko obložene tablete nateglinid
Trazec 180 mg tablets Nateglinide
Trazec 180 mg tablete nateglinid
TRAZEC 60 mg film-coated tablets
TRAZEC 60 mg filmsko obložene tablete
Trazec 60 mg film-coated tablets are pink, round tablets with “NVR” marked on one side and “TS” on the other.
Trazec 60 mg filmsko obložene tablete so rožnate, okrogle tablete z oznako “NVR” na eni ter “TS” na drugi strani.
Trazec 60 mg film-coated tablets Nateglinide
Trazec 60 mg filmsko obložene tablete nateglinid
Trazec 60 mg tablets Nateglinide
Trazec 60 mg tablete nateglinid
Trazec and older people
Trazec in starejši ljudje
Trazec can be used by people over 65 years of age.
Trazec lahko uporabljajo tudi ljudje, starejši od 65 let.
Trazec is a medicine to lower blood sugar (glucose), which is taken by mouth (these medicines are also known as oral anti-diabetics).
Trazec je zdravilo za zniževanje krvnega sladkorja (glukoze), ki ga zaužijemo (taka zdravila so znana tudi kot peroralni antidiabetiki).
Trazec tablets contain lactose monohydrate.
Tablete Trazec vsebujejo laktozo monohidrat.
Trazodone (a medicine for depression) as, unwanted effects like nausea, dizziness, low blood pressure and fainting can occur when taken with Norvir.
Trazodon (zdravilo proti depresiji), ker se lahko med sočasno uporabo z zdravilom Norvir pojavijo neželeni učinki, npr. občutek siljenja na bruhanje, omotica, nizek krvni tlak in omedlevica.
trazodone (used to treat depression)
trazodon (uporabljamo ga za zdravljenje depresije).
Trazodone 50, single dose 200 q12h ↑ 2.4-fold ↑ 34%
50, posamičen 200 na 12 ur ↑ 2,4-krat ↑ 34 % odmerek
trazodone should be considered.
previdno; v poštev pride
Trazodone single dose
Trazodon, enkraten
trazodone, a medicine used to treat depression
trazodon, zdravilo, ki se uporablja za zdravljenje depresije
trazodone, a medicine used to treat depression
trazodon; zdravilo, ki se uporablja za zdravljenje depresije
Treat all Imlygic spills with a virucidal agent and absorbent materials.
V primeru razlitja zdravila Imlygic uporabite virucidno sredstvo in vpojne materiale.
Treat bacterial infections (e.g. clarithromycin, doxycycline)
zdravljenje bakterijskih okužb (npr. klaritromicin, doksiciklin)
treat blood clots that are in your blood veins (thrombosis) or in your blood vessels in the lungs
zdravljenje krvnih strdkov v venah (tromboza) ali v krvnih žilah pljuč;
Treat cancer (e.g. cabazitaxel)
zdravljenje raka (npr. kabazitaksel)
Treat certain psychiatric disorders such as severe anxiety or schizophrenia (e.g. diazepam, midazolam, haloperidol)
zdravljenje določenih psihiatričnih motenj, npr. hude anksioznosti ali shizofrenije (npr. diazepam, midazolam, haloperidol)
Treat epilepsy (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
zdravljenje epilepsije (npr. karbamazepin, klonazepam, fenitoin, primidon, valprojska kislina)